List of Excipients in API adagrasib
✉ Email this page to a colleague
Excipients in NDA-approved (novel) drugs containing adagrasib
| Company | Tradename | Ingredient | NDC | Excipient | Potential Generic Entry |
|---|---|---|---|---|---|
| Mirati Therapeutics Inc | KRAZATI | adagrasib | 80739-812 | CELLULOSE, MICROCRYSTALLINE | 2029-12-12 |
| Mirati Therapeutics Inc | KRAZATI | adagrasib | 80739-812 | CROSPOVIDONE | 2029-12-12 |
| Mirati Therapeutics Inc | KRAZATI | adagrasib | 80739-812 | HYPROMELLOSE 2910 | 2029-12-12 |
| Mirati Therapeutics Inc | KRAZATI | adagrasib | 80739-812 | MAGNESIUM STEARATE | 2029-12-12 |
| Mirati Therapeutics Inc | KRAZATI | adagrasib | 80739-812 | MALTODEXTRIN | 2029-12-12 |
| Mirati Therapeutics Inc | KRAZATI | adagrasib | 80739-812 | MANNITOL | 2029-12-12 |
| >Company | >Tradename | >Ingredient | >NDC | >Excipient | >Potential Generic Entry |
Detailed excipient profiles for adagrasib
Excipient focus: CELLULOSE, MICROCRYSTALLINE
adagrasib drug variants containing CELLULOSE, MICROCRYSTALLINE
| Company | Ingredient | NDC |
|---|---|---|
| Mirati Therapeutics Inc | adagrasib | 80739-812 |
| >Company | >Ingredient | >NDC |
adagrasib drug variants not containing CELLULOSE, MICROCRYSTALLINE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: CROSPOVIDONE
adagrasib drug variants containing CROSPOVIDONE
| Company | Ingredient | NDC |
|---|---|---|
| Mirati Therapeutics Inc | adagrasib | 80739-812 |
| >Company | >Ingredient | >NDC |
adagrasib drug variants not containing CROSPOVIDONE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: HYPROMELLOSE 2910
adagrasib drug variants containing HYPROMELLOSE 2910
| Company | Ingredient | NDC |
|---|---|---|
| Mirati Therapeutics Inc | adagrasib | 80739-812 |
| >Company | >Ingredient | >NDC |
adagrasib drug variants not containing HYPROMELLOSE 2910
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: MAGNESIUM STEARATE
adagrasib drug variants containing MAGNESIUM STEARATE
| Company | Ingredient | NDC |
|---|---|---|
| Mirati Therapeutics Inc | adagrasib | 80739-812 |
| >Company | >Ingredient | >NDC |
adagrasib drug variants not containing MAGNESIUM STEARATE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: MALTODEXTRIN
adagrasib drug variants containing MALTODEXTRIN
| Company | Ingredient | NDC |
|---|---|---|
| Mirati Therapeutics Inc | adagrasib | 80739-812 |
| >Company | >Ingredient | >NDC |
adagrasib drug variants not containing MALTODEXTRIN
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: MANNITOL
adagrasib drug variants containing MANNITOL
| Company | Ingredient | NDC |
|---|---|---|
| Mirati Therapeutics Inc | adagrasib | 80739-812 |
| >Company | >Ingredient | >NDC |
adagrasib drug variants not containing MANNITOL
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: MEDIUM-CHAIN TRIGLYCERIDES
adagrasib drug variants containing MEDIUM-CHAIN TRIGLYCERIDES
| Company | Ingredient | NDC |
|---|---|---|
| Mirati Therapeutics Inc | adagrasib | 80739-812 |
| >Company | >Ingredient | >NDC |
adagrasib drug variants not containing MEDIUM-CHAIN TRIGLYCERIDES
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: POLYDEXTROSE
adagrasib drug variants containing POLYDEXTROSE
| Company | Ingredient | NDC |
|---|---|---|
| Mirati Therapeutics Inc | adagrasib | 80739-812 |
| >Company | >Ingredient | >NDC |
adagrasib drug variants not containing POLYDEXTROSE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: SILICON DIOXIDE
adagrasib drug variants containing SILICON DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| Mirati Therapeutics Inc | adagrasib | 80739-812 |
| >Company | >Ingredient | >NDC |
adagrasib drug variants not containing SILICON DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: TALC
adagrasib drug variants containing TALC
| Company | Ingredient | NDC |
|---|---|---|
| Mirati Therapeutics Inc | adagrasib | 80739-812 |
| >Company | >Ingredient | >NDC |
adagrasib drug variants not containing TALC
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2025 - 2026
NCE-1 Patent Challenge Dates 2025 - 2026
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2025, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch